ERBB2 and metastatic malignant neoplasm: Noticeably, T-DM1, a maytansinoid conjugated to Trastuzumab was approved specifically for the treatment of ErbB2/HER2-positive metastatic cancer [29], indicating the potential benefit of targeting this novel MTA binding site.